Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating, and neurodegenerative disease. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord. The core neuropathology of MS is the loss of oligodendrocytes and myelin sheaths, leading to axonal damage and neuroinflammation.  

InnoSer offers unique preclinical contract research services using several multiple sclerosis mouse models that show pathological de- and re-myelination. In the Cuprizone mouse model of multiple sclerosis, Cuprizone induces oligodendrocyte death and progressive and reversible myelination, recapitulating the de- and re-myelinating pathophysiology of human MS, representing a model of acute and chronic de- and re-myelination of corpus callosum. Similarly, the lysolecithin-induced mouse model of demyelination offers a rapid model with quick, reproducible and wide-spread demyelination in the central nervous system (CNS). Using the lysolecithin model, depending on the injection site, both de- and re-myelienation can be studied in different anatomical regions of mouse CNS.